SUPN Supernus Pharmaceuticals Inc
Price (delayed)
$32.82
Market cap
$1.83B
P/E Ratio
24.49
Dividend/share
N/A
EPS
$1.34
Enterprise value
$1.79B
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for
Highlights
The stock's price to earnings (P/E) is 80% less than its 5-year quarterly average of 120.4
The quick ratio has grown by 48% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of SUPN
Market
Valuations
Earnings
Shares outstanding
55.81M
Market cap
$1.83B
Enterprise value
$1.79B
Price to earnings (P/E)
24.49
Price to book (P/B)
1.75
Price to sales (P/S)
2.73
EV/EBIT
18.29
EV/EBITDA
10.04
EV/Sales
2.7
Revenue
$661.82M
Gross profit
$583.91M
Operating income
$75.56M
Net income
$73.87M
EBIT
$97.87M
EBITDA
$178.28M
Free cash flow
$171.23M
Per share
Balance sheet
Liquidity
EPS
$1.34
EPS diluted
$1.32
Free cash flow per share
$3.11
Book value per share
$18.76
Revenue per share
$12.01
TBVPS
$13.23
Total assets
$1.37B
Total liabilities
$332.34M
Debt
$27.38M
Equity
$1.04B
Working capital
$393.67M
Debt to equity
0.03
Current ratio
2.35
Quick ratio
2.04
Net debt/EBITDA
-0.24
Margins
Efficiency
Dividend
EBITDA margin
26.9%
Gross margin
88.2%
Net margin
11.2%
Operating margin
11.4%
Return on assets
5.5%
Return on equity
7.5%
Return on invested capital
28.8%
Return on capital employed
9.1%
Return on sales
14.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SUPN stock price
How has the Supernus Pharmaceuticals stock price performed over time
Intraday
3.6%
1 week
1.52%
1 month
2.37%
1 year
-1.06%
YTD
-9.24%
QTD
0.21%
Financial performance
How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$661.82M
Gross profit
$583.91M
Operating income
$75.56M
Net income
$73.87M
Gross margin
88.2%
Net margin
11.2%
SUPN's operating income is up by 33% from the previous quarter
The company's operating margin rose by 31% QoQ
The company's net income rose by 24% QoQ
The net margin is up by 22% since the previous quarter
Growth
What is Supernus Pharmaceuticals's growth rate over time
Valuation
What is Supernus Pharmaceuticals stock price valuation
P/E
24.49
P/B
1.75
P/S
2.73
EV/EBIT
18.29
EV/EBITDA
10.04
EV/Sales
2.7
The stock's price to earnings (P/E) is 80% less than its 5-year quarterly average of 120.4
The EPS is up by 24% since the previous quarter
Supernus Pharmaceuticals's equity has increased by 12% YoY and by 2.8% QoQ
SUPN's price to book (P/B) is 11% less than its 5-year quarterly average of 1.9 and 6% less than its last 4 quarters average of 1.8
Supernus Pharmaceuticals's revenue has increased by 9% YoY
The P/S is 6% below the last 4 quarters average of 2.8 and 2.2% below the 5-year quarterly average of 2.7
Efficiency
How efficient is Supernus Pharmaceuticals business performance
The return on sales is up by 33% since the previous quarter
The return on assets has grown by 20% since the previous quarter
The company's return on equity rose by 19% QoQ
SUPN's return on invested capital is up by 19% since the previous quarter
Dividends
What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SUPN.
Financial health
How did Supernus Pharmaceuticals financials performed over time
The quick ratio has grown by 48% YoY and by 9% from the previous quarter
SUPN's current ratio is up by 38% year-on-year and by 7% since the previous quarter
The debt is 97% smaller than the equity
Supernus Pharmaceuticals's debt to equity has decreased by 25% YoY
The debt is down by 18% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.